To provide enhanced protocol and trial optimization capabilities for its customers leveraging LT’s scientific, operational and drug development expertise.
Serge Bodart of IDDI provides insight on the pharma and biopharma trends impacting CROs, outsourcing in today’s market, and advances in clinical research.
Supports clinical trial continuity for biopharma companies during COVID-19 pandemic by transferring clinical trial patients to AES’ dedicated research sites
The Patient-Centered Outcomes Research Institute has funded up to $50 million to evaluate hydroxychloroquine as a preventive drug for the novel coronavirus
The first oral treatment in three distinct types of advanced prostate cancer –non-metastatic and metastatic castration-resistant prostate cancer (CRPC).